Immunotherapy: An Option for All Lung Cancer Patients?

Published on

Topics include: Treatment

Is immuontherapy an option for all lung cancer patients? Professor Charles Swanton, lung cancer researcher at Francis Crick Institute from London, explains the types of lung cancer tumors that have responded well to immunotherapy. In this therapeutic approach, the patient's immune system destroys the tumor cells. Watch as Professor Swanton offers his impressions on the future of immunotherapy in lung cancer treatment.

This interview was recorded at the European Society of Medical Oncology (ESMO) congress held in Madrid (September 2017). Breast cancer videos recorded at ESMO 17 are part of an educational program by the Patient Empowerment Foundation (PEF). We thank AstraZeneca for their support.

View more programs featuring

Transcript

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Dr. Swanton:

So for patients who have tumors that are PD-L1 positive immunotherapy provides a very important role now, and patients on the first line are following platinum resistance in patients who don't have EGFR-activated mutations or ALK rearrangements.  

These are drugs that are used more and more widely now.  They're associated with toxicities, it's true, immune—but immune toxicities such as pneumonitis, hepatitis, etc., hypophysitis, carditis and what have you. 

But if they're carefully monitored and judicial monitoring is carried out, they're relatively well tolerated and in some cases very beneficial as well.  And we're seeing, you know, some—a small proportion of patients do very well on treatment for a very long period of time, which is exciting. 

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.

Related Programs

How Do We Approach Cancer Genetic Evolution Over Time?

How can researchers attack how tumor cells become resistant to chemo over time? Professor Charles Swanton explains which strategies can be used to face this problem.

Published:

Questions to Ask Your Oncologist If You Have Lung Cancer

Which questions should you ask your oncologist if you have lung cancer? Professor Charles Swanton provides a list of useful questions.

Published:

Advertisement
Join Our Community Register For Events Read Our Latest Blog
Advertisement

Page last updated on October 23, 2017